Polypharmacology of dopamine receptor ligands
Само за регистроване кориснике
2016
Аутори
Butini, StefaniaNikolić, Katarina
Kassel, S.
Brueckmann, H.
Filipić, Slavica
Agbaba, Danica
Gemma, S.
Brogi, S.
Brindisi, M.
Campiani, G.
Stark, Holger
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, wh...ich perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.
Извор:
Progress in Neurobiology, 2016, 142, 68-103Издавач:
- Pergamon-Elsevier Science Ltd, Oxford
Финансирање / пројекти:
- EU COST Action CA 15135
- EU COST Action CM 1103
- EU COST Action CM 1207
- Синтеза, квантитативни однос између структуре и дејства, физичко-хемијска карактеризација и анализа фармаколошки активних супстанци (RS-MESTD-Basic Research (BR or ON)-172033)
- DFG - INST2018/664-1
DOI: 10.1016/j.pneurobio.2016.03.011
ISSN: 0301-0082
PubMed: 27234980
WoS: 000379093100004
Scopus: 2-s2.0-84973527131
Институција/група
PharmacyTY - JOUR AU - Butini, Stefania AU - Nikolić, Katarina AU - Kassel, S. AU - Brueckmann, H. AU - Filipić, Slavica AU - Agbaba, Danica AU - Gemma, S. AU - Brogi, S. AU - Brindisi, M. AU - Campiani, G. AU - Stark, Holger PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2738 AB - Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular. PB - Pergamon-Elsevier Science Ltd, Oxford T2 - Progress in Neurobiology T1 - Polypharmacology of dopamine receptor ligands VL - 142 SP - 68 EP - 103 DO - 10.1016/j.pneurobio.2016.03.011 ER -
@article{ author = "Butini, Stefania and Nikolić, Katarina and Kassel, S. and Brueckmann, H. and Filipić, Slavica and Agbaba, Danica and Gemma, S. and Brogi, S. and Brindisi, M. and Campiani, G. and Stark, Holger", year = "2016", abstract = "Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.", publisher = "Pergamon-Elsevier Science Ltd, Oxford", journal = "Progress in Neurobiology", title = "Polypharmacology of dopamine receptor ligands", volume = "142", pages = "68-103", doi = "10.1016/j.pneurobio.2016.03.011" }
Butini, S., Nikolić, K., Kassel, S., Brueckmann, H., Filipić, S., Agbaba, D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G.,& Stark, H.. (2016). Polypharmacology of dopamine receptor ligands. in Progress in Neurobiology Pergamon-Elsevier Science Ltd, Oxford., 142, 68-103. https://doi.org/10.1016/j.pneurobio.2016.03.011
Butini S, Nikolić K, Kassel S, Brueckmann H, Filipić S, Agbaba D, Gemma S, Brogi S, Brindisi M, Campiani G, Stark H. Polypharmacology of dopamine receptor ligands. in Progress in Neurobiology. 2016;142:68-103. doi:10.1016/j.pneurobio.2016.03.011 .
Butini, Stefania, Nikolić, Katarina, Kassel, S., Brueckmann, H., Filipić, Slavica, Agbaba, Danica, Gemma, S., Brogi, S., Brindisi, M., Campiani, G., Stark, Holger, "Polypharmacology of dopamine receptor ligands" in Progress in Neurobiology, 142 (2016):68-103, https://doi.org/10.1016/j.pneurobio.2016.03.011 . .